1. Lee JW, Eun CS (2022): Inflammatory bowel disease in Korea: epidemiology and pathophysiology. Korean J Intern Med 37: 885-894.
2.
Mak WY, Zhao M, Ng SC, Burisch J (2020): The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol 35: 380-389.
3.
Agrawal M, Jess T (2022): Implications of the changing epidemiology of inflammatory bowel disease in a changing world. United European Gastroenterol J 10: 1113-1120.
4.
Damião A, de Azevedo MFC, Carlos AS, et al. (2019): Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol 25: 1142-1157.
5.
Veauthier B, Hornecker JR (2018): Crohn’s disease: diagnosis and management. Am Fam Physician 98: 661-669.
6.
Jang DI, Lee AH, Shin HY, et al. (2021): The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci 22: 2719.
7.
Atreya R, Neurath MF (2022): IL-23 blockade in anti-TNF refractory IBD: from mechanisms to clinical reality. J Crohns Colitis 16: ii54-ii63.
8.
Robinson K, Atherton JC (2021): The Spectrum of Helicobacter-mediated diseases. Annu Rev Pathol 16: 123-144.
9.
Sharndama HC, Mba IE (2022): Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol 53: 33-50.
10.
Wang L, Cao ZM, Zhang LL, et al. (2022): Helicobacter pylori and autoimmune diseases: involving multiple systems. Front Immunol 13: 833424.
11.
Bai X, Jiang L, Ruan G, et al. (2022): Helicobacter pylori may participate in the development of inflammatory bowel disease by modulating the intestinal microbiota. Chin Med J (Engl) 135: 634-638.
12.
Guan Q (2019): A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019: 7247238.
13.
Ramos GP, Papadakis KA (2019): Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc 94: 155-165.
14.
Kim HJ, Shah SC, Hann HJ, et al. (2021): Familial risk of inflammatory bowel disease: a population-based cohort study in South Korea. Clin Gastroenterol Hepatol 19: 2128-2137.e15.
15.
Pittayanon R, Lau JT, Leontiadis GI, et al. (2020): Differences in gut microbiota in patients with vs without inflammatory bowel diseases: A Systematic Review. Gastroenterology 158: 930-946.e1.
16.
Zhou L, Zhang M, Wang Y, et al. (2018): Faecalibacterium prausnitzii produces butyrate to maintain Th17/Treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. Inflamm Bowel Dis 24: 1926-1940.
17.
Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM (2019): Escherichia coli pathobionts associated with inflammatory bowel disease. Clin Microbiol Rev 32: e00060-18.
18.
Ni J, Wu GD, Albenberg L, Tomov VT (2017): Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol 14: 573-584.
19.
Fang H, Fu L, Wang J (2018): Protocol for fecal microbiota transplantation in inflammatory bowel disease: a systematic review and meta-analysis. Biomed Res Int 2018: 8941340.
20.
Saez A, Herrero-Fernandez B, Gomez-Bris R, et al. (2023): Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci 24: 1526.
21.
Chen Y, Cui W, Li X, Yang H (2021): Interaction between commensal bacteria, immune response and the intestinal barrier in inflammatory bowel disease. Front Immunol 12: 761981.
22.
Ahluwalia B, Moraes L, Magnusson MK, Öhman L (2018): Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol 53: 379-389.
23.
Porter RJ, Kalla R, Ho GT (2020): Ulcerative colitis: recent advances in the understanding of disease pathogenesis. F1000Res 9: F1000 Faculty Rev-294.
24.
Kofla-Dłubacz A, Pytrus T, Akutko K, et al. (2022): Etiology of IBD-is it still a mystery? Int J Mol Sci 23: 12445.
25.
Slevin SM, Egan LJ (2015): New insights into the mechanisms of action of anti-tumor necrosis factor- monoclonal antibodies in inflammatory bowel disease. Inflamm Bowel Dis 21: 2909-2920.
26.
Ruder B, Atreya R, Becker C (2019): Tumour necrosis factor alpha in intestinal homeostasis and gut related diseases. Int J Mol Sci 20: 1887.
27.
Jung MK, Lee JS, Kwak JE, Shin EC (2019): Tumor necrosis factor and regulatory T cells. Yonsei Med J 60: 126-131.
28.
Billmeier U, Dieterich W, Neurath MF, Atreya R (2016): Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 22: 9300-9313.
29.
Vos AC, Wildenberg ME, Duijvestein M, et al. (2011): Anti- tumor necrosis factor- antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 140: 221-230.
30.
Castaño-Rodríguez N, Kaakoush NO, Lee WS, Mitchell HM (2017): Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis. Gut 66: 235-249.
31.
Engler DB, Leonardi I, Hartung ML, et al. (2015): Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18. Inflamm Bowel Dis 21: 854-861.
32.
Piovani D, Danese S, Peyrin-Biroulet L, et al. (2019): Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology 157: 647-659.e4.
33.
Zhong Y, Zhang Z, Lin Y, Wu L (2021): The relationship between helicobacter pylori and inflammatory bowel disease. Arch Iran Med 24: 317-325.
34.
Yang L, Zhang J, Xu J, et al. (2019): Helicobacter pylori infection aggravates dysbiosis of gut microbiome in children with gastritis. Front Cell Infect Microbiol 9: 375.
35.
Guo Y, Zhang Y, Gerhard M, et al. (2020): Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut 69: 1598-1607.
36.
Tepler A, Narula N, Peek RM, Jr., et al. (2019): Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease. Aliment Pharmacol Ther 50: 121-131.
37.
Yu Y, Zhu S, Li P, et al. (2018): Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract. Cell Death Dis 9: 961.
38.
Shirzad-Aski H, Besharat S, Kienesberger S, et al. (2021): Association between Helicobacter pylori colonization and inflammatory bowel disease: a systematic review and meta- Analysis. J Clin Gastroenterol 55: 380-392.
39.
Yamamoto-Furusho JK, Fonseca-Camarillo G, Barrera- Ochoa CA, Furuzawa-Carballeda J (2020): Synthesis of interleukin-10 in patients with ulcerative colitis and Helicobacter pylori infection. Gastroenterol Res Pract 2020: 4171083.
40.
Lin KD, Chiu GF, Waljee AK, et al. (2019): Effects of anti- Helicobacter pylori therapy on incidence of autoimmune diseases, including inflammatory bowel diseases. Clin Gastroenterol Hepatol 17: 1991-1999.
41.
Abd El-Wahab EW, Youssef EI, Hassouna E (2022): Helicobacter pylori infection in patients with inflammatory bowel diseases: a single-centre, prospective, observational study in Egypt. BMJ Open 12: e057214.
42.
Deng G, Song X, Fujimoto S, et al. (2019): Foxp3 post-translational modifications and Treg suppressive activity. Front Immunol 10: 2486.
43.
Cho KY, Cho MS, Seo JW (2012): Foxp3+ regulatory T cells in children with helicobacter pylori infection. Pediatr Dev Pathol 15: 118-126.
44.
Georgiev P, Charbonnier LM, Chatila TA (2019): Regulatory T cells: the many faces of Foxp3. J Clin Immunol 39: 623-640.
45.
Neumann C, Scheffold A, Rutz S (2019): Functions and regulation of T cell-derived interleukin-10. Semin Immunol 44: 101344.
46.
Koelink PJ, Bloemendaal FM, Li B, et al. (2020): Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut 69: 1053-1063.
47.
Hakim MS, Ding S, Chen S, et al. (2018): TNF-α exerts potent anti-rotavirus effects via the activation of classical NF-κB pathway. Virus Res 253: 28-37.
48.
Souza RF, Caetano MAF, Magalhães HIR, Castelucci P (2023): Study of tumor necrosis factor receptor in the inflammatory bowel disease. World J Gastroenterol 29: 2733-2746.
49.
Mommersteeg MC, Simovic I, Yu B, et al. (2022): Autophagy mediates ER stress and inflammation in Helicobacter pylori- related gastric cancer. Gut Microbes 14: 2015238.
50.
Triantafillidis JK, Gikas A, Merikas E (2014): Treatment of inflammatory bowel disease patients with anti-TNF-α factors and immunosuppressives does not influence the prevalence of Helicobacter pylori infection. Indian J Gastroenterol 33: 383-384.